News

Toulouse, September 3, 2026 Cell-Easy, a specialized Contract Development and Manufacturing Organization (CDMO) dedicated to cell therapy, today announced the expansion of its R&D capabilities with the addition of >50 m² of new laboratory space at its Toulouse facility. The expansion strengthens Cell-Easy’s ability to conduct multiple development and scale-up programs in parallel, supporting customers…

Toulouse, 2026 June 11th ScaleReady, a joint venture between Wilson Wolf and Bio-Techne and provider of scalable cell culture technologies, has awarded a G-Rex® Grant to Cell-Easy to support the development of a European hub for G-Rex®-based cell therapy manufacturing within the French CDMO. G-Rex® is widely recognized as a leading platform for scalable cell…

Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies directly applicable to biotech and pharma iPSC programs. Toulouse, 2026 April 14th Tackling one of the main bottlenecks in iPSC-derived therapies Scale-up remains one of the most…

CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse).…

CHU Toulouse and Cell-Easy Receive Regulatory Approval of A3D: A Phase 1 Trial Using CellReady® in Alzheimer’s Disease Cell-Easy, a Contract Development and Manufacturing Organization (CDMO) specialized in advanced cell therapies, announces that its allogeneic adipose-derived mesenchymal stem cell product, CellReady®, will be investigated in a newly approved Phase 1 clinical trial for Alzheimer’s disease.…

Cell-Easy Expands its GMP Cell Therapy Manufacturing Facility to Support Growing Client Demand New state-of-the-art class-B cleanrooms, development labs, and logistics upgrades accelerate scalable production of autologous & allogeneic cell therapies in compliance with FDA/EMA standards. Cell-Easy, a leading European Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy, today announced the expansion of its GMP…